Prediction model for para-aortic lymph node metastasis in patients with locally advanced cervical cancer

2017 ◽  
Vol 144 (1) ◽  
pp. 40-45 ◽  
Author(s):  
Seung-Hyuk Shim ◽  
Dae-Yeon Kim ◽  
Sun Joo Lee ◽  
Soo-Nyung Kim ◽  
Soon-Beom Kang ◽  
...  
Medicine ◽  
2016 ◽  
Vol 95 (39) ◽  
pp. e4814 ◽  
Author(s):  
Zhikai Liu ◽  
Ke Hu ◽  
An Liu ◽  
Jie Shen ◽  
Xiaorong Hou ◽  
...  

2020 ◽  
Vol 30 (9) ◽  
pp. 1434-1443
Author(s):  
Alejandra Martinez ◽  
Martina Aida Angeles ◽  
Denis Querleu ◽  
Gwenael Ferron ◽  
Christophe Pomel

Para-aortic lymph node status at initial assessment is the most important prognostic factor and a key point for the therapeutic strategy in patients with locally advanced cervical cancer. Undiagnosed lymph node metastasis is a major clinical problem as the finding of positive para-aortic lymph nodes leads to treatment modification, with a possible impact on disease free survival. When aortic lymph node disease is discovered, radiotherapy is extended to the para-aortic area, and other treatment modalities may be considered. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is the most accurate imaging examination to assess para-aortic extension in patients with locally advanced cervical cancer. The gold standard to identify para-aortic extension remains histologic evaluation of the lymph nodes. Indeed, PET/CT fails to detect approximately 10–15% of patients with negative PET/CT aortic nodes who have lymph node metastasis on pathologic staging. Patients with positive pelvic lymph nodes have para-aortic extension in 25–30% of cases, and surgical staging will lead to treatment modification and probably to improved para-aortic and distant control. Surgical staging also avoids unnecessary toxicity associated with extended field radiation in approximately 75% of patients with pelvic lymph node metastasis. The best modality to identify para-aortic extension is histological evaluation of the lymph nodes, but the survival benefit of surgical staging remains controversial. On the other hand, current studies include a majority of patients without pelvic lymph node spread, who are likely to be those who will benefit the least from surgical staging.


2015 ◽  
Vol 16 (11) ◽  
pp. 4719-4722 ◽  
Author(s):  
Navamol Lekskul ◽  
Chuenkamon Charakorn ◽  
Arb-Aroon Lertkhachonsuk ◽  
Sasivimol Rattanasiri ◽  
Nathpong Israngura Na Ayudhya

2020 ◽  
Vol 30 (8) ◽  
pp. 1136-1142
Author(s):  
Noriaki Sakuragi ◽  
Masanori Kaneuchi ◽  
Tatsuya Kato ◽  
Chisa Shimada ◽  
Yukiharu Todo ◽  
...  

ObjectiveThe survival and prognostic factors for locally advanced cervical cancer treated with nerve-sparing Okabayashi–Kobayashi radical hysterectomy have not been elucidated. We aimed to evaluate the oncological outcomes of those patients after radical hysterectomy with adjuvant chemotherapy.MethodsThis retrospective cohort study was conducted from January 2002 to December 2011. Treatment was conducted at a single tertiary center in northern Japan. We used the Okabayashi–Kobayashi radical hysterectomy with lymphadenectomy. We applied unilateral nerve preservation for stage IIA/IIB cancer if there was a one-sided extension of the disease outside the cervix. Indication for adjuvant therapy was based on Sedlis criteria. High-risk was defined as evidence of lymph node metastasis, pathological parametrial invasion, and a positive/close surgical margin. The choice of adjuvant therapy was chemotherapy which consisted of paclitaxel and cisplatin.ResultsThe study included 76 early-stage IB1 (≤4 cm) and IIA1 cervical cancer and 45 locally advanced stage IB2 (>4 cm), IIA2, and IIB disease treated consecutively. The median follow-up was 106 (range: 6-203) months. There were 18 (15%) patients with recurrence, with five of 76 in the early-stage (7%) and 13 of 45 in the locally advanced disease (29%) (P<0.001). For locally advanced cervical cancer, pT classification (P<0.001), lymph node metastasis (P=0.007), and histology (P=0.05) were associated with locoregional recurrence. The five-year locoregional recurrence rate in the locally advanced disease was 20% and 5% in the early-stage disease (P=0.01). The five-year disease-free survival in the locally advanced cervical cancer was 71% and 93% in the early-stage disease (P<0.001). The overall survival in locally advanced disease depended on the adeno-type histology and lymph node metastasis.ConclusionThe tailored use of nerve-sparing Okabayashi–Kobayashi radical hysterectomy with adjuvant chemotherapy based on tumor histology and lymph node metastasis may be a possible option as a treatment of locally advanced cervical cancer in selected patients.


2015 ◽  
Vol 138 (2) ◽  
pp. 299-303 ◽  
Author(s):  
Armin Vandeperre ◽  
Erik Van Limbergen ◽  
Karin Leunen ◽  
Philippe Moerman ◽  
Frédéric Amant ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document